Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics and involved all existing investors including TIME Ventures, Seventure, and Global Brain.

Congratulations to founder Susan Lynch, PhD, the UCSF principal investigator, and her co-founder Nikole Kimes, PhD, the grad student who took this technology and launched a company with it. Kimes is now the CEO of Siolta.